Moderna, Curia and Abzena are among the companies welcoming new faces to top jobs.
Moderna, Curia and Abzena are among the companies welcoming new faces to top jobs.
Moderna has appointed James Mock as its new Chief Financial Officer, beginning September 6, 2022.
He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel.
Following the appointment of Mr. Mock, David Meline will retire as the company's CFO but will remain as a consultant to assist with the transition.
Prior to joining Moderna, Mr. Mock served as Senior Vice President and CFO of PerkinElmer, Inc., (NYSE:PKI) a life sciences, diagnostics and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all company finance functions.
Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the US and overseas.
Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University.
Chan Lee has taken on the role as General Counsel at BeiGene.
Lee joins BeiGene from Sanofi and will bring his expertise leading legal functions in the biopharma industry to overseeing legal, compliance, intellectual property and related matters. He succeeds Scott Samuels, who built BeiGene’s global legal and compliance team and served as an important part of the company’s evolution to a global commercial organization.
Lee most recently served as North America General Counsel and Head of Legal for Specialty Care Global Business Unit at Sanofi, responsible for the legal oversight of Sanofi’s operations in the US and Canada and Specialty Care business globally. Prior to Sanofi, he held roles of increasing responsibility at Pfizer, most notably as Chief Counsel for Pfizer's Innovative Health global business. Earlier in his career, he served as Chief Counsel for the Vaccines, Oncology and Consumer Health global businesses at Pfizer, as well as Assistant General Counsel for its Asia operations.
Lee will serve on BeiGene’s Executive Committee and report directly to co-founder, chairman and CEO John V. Oyler.
Evonetix, a synthetic biology company bringing semiconductor technology to DNA synthesis, has appointed Colin McCracken as Chief Executive Officer.
The appointment will support the next phase of the company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
McCracken brings over 20 years’ experience in commercial and business development roles. Prior to joining Evonetix he was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Company’s global reach. He has delivered commercial success in numerous leadership positions, including Vice President and General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President and Head of European Sales at Life Technologies and National Sales Manager at Qiagen.
As CEO of Evonetix, Colin will focus on building strategic partnerships and customer relationships, ahead of the commercial introduction of the Company’s first product, a benchtop DNA printer. The announcement comes as Evonetix continues to strengthen its senior leadership team, following the recent appointment of Paul Beastall as Chair, as the Company enters the next phase of its development, moving from pure research and development into product commercialisation.
CDMO Curia (formerly AMRI) has announced the appointment of Niall Condon as president of its Manufacturing Division, with immediate effect.
Condon will drive growth and be responsible for operational delivery of Curia’s commercial manufacturing services and products, including API and Drug Product. He will serve as a member of Curia’s executive committee. Condon succeeds Curia’s retiring president of Manufacturing, Steve Lichter.
Condon most recently served as head of API and OSD Manufacturing at Viatris, which was formed through the merger of Mylan and Upjohn Pfizer. Previously, he was a senior vice president at Pfizer, where he built a standalone global supply organization, the Upjohn Division. Condon spent more than 30 years at Pfizer in roles of increasing responsibility in manufacturing and operations, based at locations in the US, Europe and Asia. He earned his Bachelor of Science in Chemical Engineering at Munster Technological University, Ireland, and his Master of Business Administration at Rensselaer Polytechnic Institute, New York.
Partner Research Organization (PRO) Abzena has appointed Jeffrey Mocny, Ph.D., as scientific lead.
Reporting to Abzena’s Head of Scientific Leaders, Dr. Petra Dieterich, Dr Mocny will use his experience with biopharmaceutical regulations to support the company’s drug development and manufacturing operations.
Dr. Mocny most recently served as senior vice president, regulatory affairs at ProEd Regulatory, a communications agency with expertise in medical communications and strategy.
He joins Abzena with more than three decades’ experience of working in drug development with a focus on regulatory strategy. A PhD microbiologist by training, Jeff has wide-ranging experience in working in a CRO environment across different stages of the drug development and manufacturing lifecycle including analytical method development, CMC regulatory affairs and IP to Phase I.
Abzena provides integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs).
The Biotechnology Innovation Organization (BIO) has elected its new Executive Committee directors for the 2022-2023 term: with the directors chosen during the 2022 BIO International Convention in San Diego in June.
“On behalf of our entire BIO organization, I want to congratulate our incoming Board directors and section leaders,” said Dr. Michelle McMurry-Heath, President & CEO of BIO. “This is a critical time for our industry. Our BIO Board – especially one as diverse and multi-faceted as this one – will help drive policies that keeps pace with innovation’s promise to cure disease, nourish society, and protect our planet.”
BIO’s Executive Committee directors for the 2022-2023 term are:
- Paul Hastings, Nkarta Therapeutics – Board Chair/Health Section Chair
- Elizabeth Lewis, Takeda Pharmaceuticals – Board Associate Vice Chair & Secretary
- Bradford Zakes, Ceravast Medical – BIO Board Treasurer
- Ted Love, Global Blood Therapeutics – Health Section Vice Chair
- Sylvia Wulf, AquaBounty Technologies – Agriculture & Environment Section Chair
- John Crowley, Amicus Therapeutics – Emerging Companies Section Chair
- Jeremy Levin, Ovid Therapeutics – Immediate Past Chair
- Erika Smith, ReNetX BIO – Emerging Companies Section Vice Chair
- Anna Rath, Vestaron
- Doug Doerfler, MaxCyte
- Stuart Arbuckle, Vertex Pharmaceuticals
- Christi Shaw, Kite, A Gilead Company
- Bill Sibold, Genzyme, A Sanofi Company
- Fritz Bittenbender, Genentech Roche
- Chris Boerner, Bristol Myers Squibb
- Eric Dube, Travere Therapeutics
- Sue Washer, Applied Genetic Technologies Corporation (AGTC)
- Aamir Malik, Pfizer
- Jannie Oosthuizen, Merck
- Victor Bulto, Novartis Pharmaceuticals
- Bill Newell, Sutro BioPharma
Additional directors who were confirmed as the Executive Advisory Board (EAB) to the Executive Committee:
- Ron Cohen, Acorda Therapeutics
- Rachel King, former BIO Board Chair
- John Maraganore, former BIO Board Chair
- Richard Pops, Alkermes
Newly Elected to the BIO Health Section Governing Board (2022-2025 Term):
- Jannie Oosthuizen, Merck
Newly Elected to the BIO Emerging Companies Section Governing Board (2022-2023 Term):
- Pablo Cagnoni, Rubius Therapeutics
- Kaye Foster, The Boston Consulting Group
- Mike Huckman, Real Chemistry
- Elizabeth Jeffords, Iolyx Therapeutics
- Sheila Mikhail, Asklepios BioPharmaceutical
Newly Elected to the BIO Agriculture and Environment Section Governing Board (2022-2024 Term):
- Angela Ailloni, Ginkgo Bioworks
- Rocco Morelli, Recombinetics
CDMO Scorpion Biological Services appointed Stephan Kutzer, Ph.D., as Interim CEO in June.
Dr. Kutzer currently serves on Scorpion's advisory board.
He brings more than 25 years of experience in the pharmaceutical and biotech industries, managing successful contract development and manufacturing organizations. He previously served as President and CEO of Alcami Corporation, a leading provider of development, analytical testing, and manufacturing services to the pharmaceutical and biotech industries. Prior to this, he served as President, Divisional CEO and Chief Operating Officer of the Pharma Biotech & Customer Manufacturing division of Lonza Group AG, a multinational manufacturing company serving the pharmaceutical and biotechnology sectors, where he had full oversight of the division, which generated over $1.6bn in annual sales.
Dr. Kutzer also served as a member of the Executive Management Board of Lonza Group AG; President of Lonza Biologics Inc; Chairman of the Board of Directors of Lonza Singapore Inc; Chairman of the Board of Directors of Teva-Lonza TL Biopharmaceuticals AG; Chairman of the Board of Directors of Lonza Biologics plc.; and President and Chairman of Lonza Inc. He previously served as an Executive Director on the board of directors for the Drug, Chemical & Associated Technologies Association (DCAT). Dr. Kutzer earned a master's degree in Chemical and Process Engineering and a Ph.D. in Engineering Sciences from the Technical University of Munich, Germany.